1229 related articles for article (PubMed ID: 25585064)
1. Correlates of human papillomavirus vaccine coverage: a state-level analysis.
Moss JL; Reiter PL; Brewer NT
Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064
[TBL] [Abstract][Full Text] [Related]
2. Differences in Human Papillomavirus Vaccination Among Adolescent Girls in Metropolitan Versus Non-metropolitan Areas: Considering the Moderating Roles of Maternal Socioeconomic Status and Health Care Access.
Monnat SM; Rhubart DC; Wallington SF
Matern Child Health J; 2016 Feb; 20(2):315-25. PubMed ID: 26511129
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
Kim JJ; Goldie SJ
BMJ; 2009 Oct; 339():b3884. PubMed ID: 19815582
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide.
Owsianka B; Gańczak M
Przegl Epidemiol; 2015; 69(1):53-8, 151-5. PubMed ID: 25862448
[TBL] [Abstract][Full Text] [Related]
9. Race, ethnicity, and income factors impacting human papillomavirus vaccination rates.
Jeudin P; Liveright E; Del Carmen MG; Perkins RB
Clin Ther; 2014 Jan; 36(1):24-37. PubMed ID: 24417783
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
Luttjeboer J; Westra TA; Wilschut JC; Nijman HW; Daemen T; Postma MJ
Vaccine; 2013 Aug; 31(37):3922-7. PubMed ID: 23806241
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia.
Aljunid S; Maimaiti N; Nur AM; Noor MRM; Wan Puteh SE
BMC Public Health; 2016 Jan; 16():71. PubMed ID: 26803814
[TBL] [Abstract][Full Text] [Related]
12. Inter-state variation in human papilloma virus vaccine coverage among adolescent girls in the 50 US states, 2007.
Kramer MR; Dunlop AL
Matern Child Health J; 2012 Apr; 16 Suppl 1():S102-10. PubMed ID: 22453332
[TBL] [Abstract][Full Text] [Related]
13. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
16. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany.
Largeron N; Petry KU; Jacob J; Bianic F; Anger D; Uhart M
Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):85-98. PubMed ID: 27366939
[TBL] [Abstract][Full Text] [Related]
17. Community-based household assessment of human papillomavirus (HPV) vaccination coverage and acceptability - HPV vaccine demonstration program, Cambodia - 2017.
Garon J; Wuddhika IV; Sreenivasan N; Wannemuehler K; Vutthikol Y; Chhorvann C; Loharikar A
Vaccine; 2019 Feb; 37(9):1202-1208. PubMed ID: 30686637
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.
Setiawan D; Luttjeboer J; Westra TA; Wilschut JC; Suwantika AA; Daemen T; Atthobari J; Wilffert B; Postma MJ
Expert Rev Vaccines; 2015 Apr; 14(4):589-604. PubMed ID: 25482311
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus vaccine uptake in boys and girls in a school-based vaccine delivery program in Prince Edward Island, Canada.
McClure CA; MacSwain MA; Morrison H; Sanford CJ
Vaccine; 2015 Apr; 33(15):1786-90. PubMed ID: 25731789
[TBL] [Abstract][Full Text] [Related]
20. Health and economic implications of HPV vaccination in the United States.
Kim JJ; Goldie SJ
N Engl J Med; 2008 Aug; 359(8):821-32. PubMed ID: 18716299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
